Pfizer has launched its new 20-valent Pneumococcal Conjugate Vaccine (PCV20) for adults in India.

This next-generation, single-dose vaccine offers broad protection against 20 serotypes of pneumococcal disease, surpassing coverage of previous conjugate vaccines in India.

This is a crucial development for adults, particularly those with chronic health conditions, aiming to significantly reduce the risk of severe illness and hospitalizations.

The launch strengthens Pfizer's commitment to preventive health and reinforces its leadership in vaccine innovation, addressing a key public health need.